HNRNPU K181 Lactylation Drives Serine Metabolic Rewiring in Cervical Cancer

Study Background and Research Question

Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to sustain rapid proliferation and adapt to microenvironmental stresses. In cervical cancer, aberrant metabolism—particularly increased glycolysis and subsequent lactate accumulation—supports tumor growth and progression. Recent discoveries have identified lactylation, a novel post-translational modification (PTM) of lysine residues, as a mechanism by which lactate exerts non-metabolic regulatory effects in cancer biology. While histone lactylation has been associated with gene regulation, the functional significance of non-histone protein lactylation in cervical cancer remains poorly defined. The central research question addressed by Zhang et al. (2026) is how lysine lactylation of heterogeneous nuclear ribonucleoprotein U (HNRNPU) at position K181 contributes to cervical cancer progression, and what molecular mechanisms underlie this effect.

Key Innovation from the Reference Study

The reference study provides the first direct evidence that HNRNPU, a non-histone RNA-binding protein, undergoes functionally significant lysine lactylation at residue K181 in cervical cancer. This modification stabilizes HNRNPU, enhances its binding to the mRNA of phosphoglycerate dehydrogenase (PHGDH)—the rate-limiting enzyme in serine biosynthesis—and promotes the maintenance of PHGDH exon 1-containing transcripts. This axis forms a metabolic regulatory loop, linking lactate accumulation with serine metabolism and thereby fostering tumor cell proliferation. Furthermore, the authors reveal a dynamic competition between lactylation and NAA50-mediated acetylation at HNRNPU K181, providing a new perspective on PTM crosstalk in cancer.

Methods and Experimental Design Insights

To elucidate the role of HNRNPU K181 lactylation, the authors employed a multi-layered experimental approach:

• Transcriptomic and proteomic profiling: Expression of splicing factor families was assessed in cervical cancer tissues using GEPIA and PRIDE databases, highlighting the HNRNP family as highly expressed at the protein level.
• PTM mapping and validation: Mass spectrometry identified HNRNPU as a non-histone substrate of lysine lactylation, specifically at K181. Site-directed mutagenesis and custom antibodies were used to confirm the modification in cell-based and tissue samples.
• RNA binding and functional assays: RNA immunoprecipitation (RIP) and crosslinking experiments established that HNRNPU K181 lactylation enhances its affinity for PHGDH mRNA. Knockdown and rescue strategies, along with PHGDH reporter constructs, demonstrated functional consequences for serine biosynthesis and cellular proliferation.
• PTM interplay analysis: The study probed the competition between lactylation and NAA50-mediated acetylation at K181, using acetyltransferase inhibitors and overexpression systems.
• In vivo validation: Xenograft mouse models were used to confirm the tumor-promoting effects of HNRNPU K181 lactylation and the suppressive impact of pharmacological inhibition using Pazopanib.

Protocol Parameters

• HNRNPU lactylation detection: Use PTM-specific antibodies for immunoblotting and immunofluorescence in cervical cancer cell lysates and tissues.
• Site-directed mutagenesis: Introduce K181R (lactylation-deficient) and K181Q (lactylation-mimetic) mutations in HNRNPU constructs for functional assays.
• RNA immunoprecipitation: RIP performed following crosslinking with formaldehyde, using anti-HNRNPU or anti-Kla antibodies; analyze PHGDH mRNA enrichment by qPCR.
• Xenograft protocol: Inject 1 × 10⁶ cervical cancer cells subcutaneously into immunodeficient mice; monitor tumor volume with or without pharmacological inhibitors (e.g., Pazopanib at 50 mg/kg, orally, daily).
• Metabolite quantification: Measure intracellular serine and lactate levels using LC-MS or colorimetric kits in cell lysates after experimental manipulations.
• PHGDH mRNA stability assays: Treat cells with actinomycin D (5 μg/mL) and assess PHGDH mRNA decay by qPCR over time.

Core Findings and Why They Matter

The principal discoveries of the study are:

• HNRNPU is a functionally relevant non-histone substrate for lysine lactylation in cervical cancer, with this modification occurring predominantly at K181.
• K181 lactylation stabilizes HNRNPU and increases its binding to PHGDH mRNA, thereby promoting the expression of the serine biosynthesis enzyme PHGDH.
• The resulting serine metabolic rewiring enhances redox homeostasis, nucleotide synthesis, and cell proliferation, supporting cervical cancer progression both in vitro and in vivo.
• Post-translational modification crosstalk is observed: NAA50-mediated acetylation at K181 antagonizes lactylation, suggesting a regulatory switch that fine-tunes HNRNPU function.
• Pharmacological inhibition of HNRNPU K181 lactylation with Pazopanib suppresses PHGDH expression and tumor growth, highlighting translational potential for targeting this axis.

These findings illuminate a previously uncharacterized lactate-driven signaling pathway that integrates metabolic and post-transcriptional regulation, underscoring new therapeutic possibilities for cervical and potentially other malignancies (internal review).

Comparison with Existing Internal Articles

Several internal articles have contextualized these mechanisms within the broader landscape of metabolic regulation and proteasome function in cancer. For example, the review "HNRNPU K181 Lactylation Drives Serine Metabolic Rewiring in Cervical Cancer" synthesizes these findings, emphasizing the role of lactylation in stabilizing PHGDH mRNA and facilitating cancer cell proliferation. Another perspective (see here) highlights the translational implications for metabolic targeting. While these articles primarily focus on the lactylation-metabolism axis, other internal resources discuss methodological rigor in ubiquitin-proteasome system research, including the use of stereoisomeric proteasome inhibitors such as (R)-MG132. These tools are critical for distinguishing specific from off-target effects in mechanistic studies involving post-translational modification and protein turnover (see example).

Limitations and Transferability

Despite the strength of the multi-modal experimental approach, several limitations merit consideration:

• Cancer type specificity: The study focuses exclusively on cervical cancer; whether HNRNPU K181 lactylation exerts similar metabolic effects in other cancers requires further investigation.
• PTM detection sensitivity: Antibody-based lactylation detection may have off-target recognition; careful validation is necessary for broader application.
• Pharmacological tool specificity: Pazopanib is a multi-kinase inhibitor; its effect on lactylation may involve indirect mechanisms beyond the studied axis.
• In vivo model limitations: Xenograft systems do not fully recapitulate the tumor microenvironment and immune context of human cervical cancer.

Nevertheless, the mechanistic insights into PTM crosstalk and metabolic regulation are likely to inform future research in cancer metabolism and RNA-binding protein function.

Research Support Resources

For researchers seeking to dissect proteasome-dependent versus off-target effects in post-translational modification and metabolic studies, functionally inactive negative controls are indispensable. (R)-MG132 (SKU C3348), a stereoisomeric MG-132 enantiomer with minimal 20S proteasome inhibitory activity, serves as an established negative control in ubiquitin-proteasome system research and cell-based assay proteasome control workflows. According to the APExBIO product information, its use helps validate the specificity of proteasome inhibition and supports the mechanistic rigor required for studies such as those described above.